Cardiac Manifestations of Coronavirus Disease 2019 (COVID-19): a Multicenter Cohort Study

BACKGROUND: This study aimed to investigate the cardiac manifestations of coronavirus disease 2019 (COVID-19) METHODS: From February to March 2020, we prospectively and retrospectively enrolled consecutive patients diagnosed with COVID-19 Patient's data such as the demographic characteristics, symptoms, vital signs, laboratory and radiologic findings, electrocardiographic, and echocardiographic data, including the global longitudinal strain (GLS) of both ventricles, were obtained RESULTS: Forty patients (median age, 58 years;50% men) were enrolled in the initial analysis Patients were classified into severe and nonsevere groups based on the current guidelines The 13 patients in the severe group were significantly older, had a greater prevalence of bilateral pneumonia and leukocytosis, and higher aspartate transaminase levels than patients in the nonsevere group Patients in the severe group had a slightly lower left ventricular ejection fraction (LVEF) than those in the nonsevere group (median [interquartile range], 61 0% [58 5%, 62 3%] vs 66 7% [60 6%, 69 8%], P = 0 015) In a subgroup of 34 patients in whom GLS could be analyzed, patients in the severe group had a significantly impaired left ventricular GLS (LVGLS) than those in the nonsevere group (-18 1% [-18 8%, -17 1%] vs -21 7% [-22 9%, -19 9%], P = 0 001) There were no significant differences in total wall (RVGLStotal, -19 3% [-23 9%, -18 4%] vs -24 3% [-26 0%, -22 6%], P = 0 060) and free wall (RVGLSfw, -22 7% [-27 2%, -18 6%] vs -28 8% [-30 4%, -24 1%], P = 0 066) right ventricle GLS (RVGLS) CONCLUSION: Patients with severe COVID-19 had lower LVEF and LVGLS RVGLS was not different between patients with severe and nonsevere COVID-19